Stock Taper
PepGen Inc. is a Cambridge-based biotech developing oligonucleotide therapeutics, including PGN-EDO51 for Duchenne muscular dystrophy and other candidates for neuromuscular and neurologic diseases.

PGN-EDODM1 is an investigational peptide-conjugated oligonucleotide therapeutic in clinical trials for Myotonic Dystrophy Type 1, now PepGen’s lead candidate after discontinuing its Duchenne muscular dystrophy program.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
FATE | $2.43 | COMPARE |
ALEC | $2.34 | COMPARE |
CRBP | $10.91 | COMPARE |
NKTX | $2.76 | COMPARE |
MOLN | $4.50 | COMPARE |
CRDF | $0.94 | COMPARE |
ELTX | $2.84 | COMPARE |